Healthcare Industry News: NovaCardia
News Release - January 3, 2008
Montreux Equity Partners Closes $250 Million MEP IV Life Sciences FundMENLO PARK, Calif.--(HSMN NewsFeed)--Montreux Equity Partners, L.L.C. (“Montreux” or “MEP”), today announced the close of Montreux Equity Partners IV, L.P. (“MEP IV”), a $250 million venture capital fund focused on therapeutic-oriented life sciences companies. With strong support from existing investors and new institutional investors, MEP IV exceeded its $200 million target and closed at its hard cap of investor commitments.
“We appreciate the support of our limited partners, who are attracted to our investment approach and performance,” said Daniel K. Turner III, Managing Director at Montreux Equity Partners. “We look forward to working with outstanding entrepreneurs to build companies with innovative therapeutic products that improve the lives of patients.”
Montreux has built a successful track record of investing in therapeutic-oriented companies with several notable exits. These include, more recently, the acquisitions of Cerexa (Forest Laboratories), NovaCardia (Merck) and Peninsula Pharmaceuticals (Johnson & Johnson) as well as a number of Initial Public Offerings, including Orexigen Therapeutics (NASDAQ:OREX ). MEP IV already has invested in several companies including Glaukos and Avantis Medical in the medical device sector as well as pharmaceutical companies Tobira Therapeutics and Sequel Pharmaceuticals.
“We are impressed with the Montreux team and their history of investing in high-quality life sciences companies,” said Michael J. Kelly, Managing Director of Hamilton Lane. “Health care markets continue to expand globally, driven by demographic trends and technological advancements. We are excited to be working with Montreux as the firm pursues these opportunities.”
The Montreux team includes Managing Directors Manish Chapekar, Howard Palefsky, John Savarese, M.D., and Daniel K. Turner III.
Lazard Frères & Co., L.L.C., acted as placement agent for Montreux.
About Montreux Equity Partners:
Montreux Equity Partners is a venture capital firm focused on investing in therapeutic-oriented life sciences companies. The investment team at Montreux Equity Partners includes Manish Chapekar, Howard Palefsky, John Savarese, M.D., and Daniel K. Turner III. The firm's investment team brings more than 60 years of operating and investing experience as entrepreneurs, managers and investors to their portfolio companies. Montreux Equity Partners has offices located in Menlo Park, California. For more information about Montreux Equity Partners, visit www.mepvc.com.
Source: Montreux Equity Partners
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.